Corporate GovernanceApr 30, 2026, 04:37 PM
CPRX Amends 10-K to Detail Governance, Executive Comp
AI Summary
CATALYST PHARMACEUTICALS, INC. filed Amendment No. 1 to its 2025 Form 10-K to include information for Part III, Items 10 through 14, which cover Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Principal Accountant Fees. The amendment also includes new certifications from the principal executive and financial officers. It details the company's executive compensation philosophy and the 2025 corporate goals for cash bonuses, which included revenue targets for FIRDAPSE® and AGAMREE®.
Key Highlights
- Amendment filed to include Part III items (10-14) in 2025 Annual Report.
- Details provided on Directors, Executive Officers, and Corporate Governance.
- Executive compensation process for 2025 outlined, using Mercer LLC.
- 2025 corporate bonus goals included $573.5M total revenue target.
- FIRDAPSE® net revenue target set at $362.9M for 2025.
- AGAMREE® net product revenue target set at $122.1M for 2025.
- Management bonuses for 2025 performance set at 100% of target.
- New certifications of principal executive and financial officers filed.
Price Impact
More from CPRX